SignaBlok has an expanding, deep and diversified pipeline of new chemical entity (NCE) assets leveraging SignaBlok's proprietary technologies to image macrophages and shape their biology in multiple inflammation-associated diseases and disorders where macrophages are centrally involved.
![](https://signablok.com/wp-content/uploads/2020/12/signablok-pipeline-2nd-draft-1536x684.png)